Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with documented stable chronic heart failure (NYHA II-IV):
* LVEF ≥ 45% (local measurement, assessed by echocardiography, MUGA, CT scan, MRI or ventricular angiography)
* the ejection fraction must have been obtained within 6 months prior to randomization or after any MI or other event that would affect ejection fraction.
Plasma NT-proBNP \> 500 pg/ml at Visit 1.
Patients with documented stable chronic heart failure (NYHA II-IV).
Patients receiving ACE inhibitors (ACEi), an angiotensin receptor blockers (ARB) and/or a beta blockers must be on a stable dose of these medications stable for the 1 month period prior to Visit 1.
Patients must be on diuretic therapy prior to Visit 1 (flexible dosing is permitted).
Patients with a controlled systolic BP, defined as a target systolic BP less than 140 mm Hg; participants with BP up to and including 160 mm Hg are eligible for enrollment if they are on three or more medications to control BP at randomization (Visit 2).
Patients with at least one of the following symptoms at the time of screening (Visit 1):
* Dyspnea on exertion
* Orthopnea
* Paroxysmal nocturnal dyspnea
* Peripheral edema
Patients must have an eGFR ≥ 30 ml/min/1.73 m2 at Visit 1 (calculated by the Modification of Diet in Renal Disease formula).
Patients with a potassium ≤5.2 mmol/l at Visit 1.
You may not be if
Patients with a prior LVEF reading \<45%, at any time.
Patients who require treatment with both an ACE inhibitor and an ARB.
Isolated right heart failure due to pulmonary disease.
Dyspnea and/or edema from non-cardiac causes, such as lung disease, anemia, or severe obesity.
Presence of hemodynamically significant mitral and /or aortic valve disease.
Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic stenosis.
Presence of hypertrophic obstructive cardiomyopathy.
Clareo Health | LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
